Agenus to Participate at BTIG Biotechnology Conference
Agenus (NASDAQ: AGEN), an immuno-oncology company, will participate virtually in the BTIG Biotechnology Conference and hold one-on-one meetings with investors on August 9, 2022, following its second quarter corporate update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agenus (NASDAQ: AGEN), an immuno-oncology company, will participate virtually in the BTIG Biotechnology Conference and hold one-on-one meetings with investors on August 9, 2022, following its second quarter corporate update. The company focuses on developing therapies that activate the immune system to combat cancer and infections, utilizing a combination of antibody therapeutics, adoptive cell therapies, and adjuvants. Agenus is headquartered in Lexington, MA, and aims to expand access to cancer immunotherapy.
Details
News Market Reaction – AGEN
The recorded move for AGEN in the trading session of this news was +3.63%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will attend the BTIG Biotechnology Conference. Agenus will participate virtually and host one-on-one meetings with investors following its second quarter 2022 corporate update on the morning of August 9.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
Contact
Ethan Lovell
Chief Corporate Affairs & Communications Officer
339-927-1763
ethan.lovell@agenusbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.